Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0IQGNU
|
|||||
---|---|---|---|---|---|---|
ADC Name |
WO2007011968A2 cAC10-17
|
|||||
Synonyms |
WO2007011968A2 cAC10-17
Click to Show/Hide
|
|||||
Organization |
Seagen Inc.
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 1 Indication(s)
Anaplastic large cell lymphoma [ICD11:2A90]
Investigative
|
|||||
Drug-to-Antibody Ratio |
6.8
|
|||||
Antibody Name |
Brentuximab
|
Antibody Info | ||||
Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
Payload Name |
Doxorubicin
|
Payload Info | ||||
Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
Linker Name |
WO2007011968A2_cAC10-17 linker
|
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.20 nM | Positive CD30 expression (CD30+++/++); Negative CD70 expression (CD70-) | ||
Method Description |
Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
|
||||
In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 45.00 nM | Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-) | ||
Method Description |
Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
|
||||
In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 45.00 nM | Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-) | ||
Method Description |
Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
|
||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.